Sergio Mallart

USPTO Granted Patents = 15 (Patent Applications = 2)

CIPO Patents = 1 (Patent Applications = 2)

EPO Patents = 4 (Patent Applications = 5)

Average Co-Inventor Count = 6.8

ph-index = 4

Forward Citations = 31(Granted Patents)

Location History:

Orsay, FR (1994 - 2011)
Paris, FR (2015 - 2023)

Company Filing History:

Societe Nationale Elf Aquitaine

Years Active: 1994-2023

Loading Chart...

15 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 11725036 - Modified lipidated relaxin B chain peptides and their therapeutic use (2023-08-15),

2. 10988524 - Modified relaxin B chain peptides and their therapeutic use (2021-04-27),

3. 10988523 - Modified lipidated Relaxin B chain peptides and their therapeutic use (2021-04-27),

4. 10980816 - Thienopyrimidine derivatives, processes for the preparation thereof and therapeutic uses thereof (2021-04-20),

5. 10961295 - Modified lipidated Relaxin B chain peptides and their therapeutic use (2021-03-30),

6. 10736904 - Thienopyrimidine derivatives, processes for the preparation thereof and therapeutic uses thereof (2020-08-11),

7. 10500212 - Thienopyrimidine derivatives, processes for the preparation thereof and therapeutic uses thereof (2019-12-10),

8. 10220044 - Thienopyrimidine derivatives, processes for the preparation thereof and therapeutic uses thereof (2019-03-05),

9. 9744176 - Therapeutic uses of novel thienopyrimidine derivatives (2017-08-29),

10. 9150544 - Sulphonylaminopyrrolidinone derivatives, their preparation and their therapeutic application (2015-10-06),

11. 9115140 - Thienopyrimidine derivatives, processes for the preparation thereof and therapeutic uses thereof (2015-08-25),

12. 8076324 - Di(hetero)arylcyclohexane derivatives, their preparation, their use and pharmaceutical compositions comprising them (2011-12-13),

13. 5543526 - 1-amino-4-(1H-imidazole)- aminobutaneboronic acid derivatives, their (1996-08-06),

14. 5426216 - Process for the hydrogenation of ethylenically unsaturated organic (1995-06-20),

15. 5324850 - Preparation of chiral catalysts based on ruthenium and phosphorus (1994-06-28),

Title: Sergio Mallart: A Pioneer in Biochemical Innovations

Introduction

Sergio Mallart, a distinguished inventor based in Paris, France, has made significant contributions to the field of biochemistry. With a remarkable portfolio of 15 patents, he has been at the forefront of developing innovative therapeutic peptides, particularly in the area of lipidated Relaxin B chain peptides.

Latest Patents

Sergio's latest patents include "Modified lipidated relaxin B chain peptides and their therapeutic use." This invention presents a biologically active single-chain Relaxin peptide with the formula N-Ac-L-E-G-R-E-K-V-R-A-X-I-X-X-E-G-X-S-T-F-S-X-R-A-X-NH-C, or a salt or solvate thereof. Another notable patent under his name is also titled "Modified lipidated Relaxin B chain peptides and their therapeutic use," which describes a similar biologically active single-chain Relaxin peptide with the formula N-Ac-(E)-X-E-G-R-E-X-V-R-X-X-I-X-X-E-G-X-S-X-X-X-X-R-(X)-(X)-(K)-(X)-(gE)-X-C; or a salt or solvate thereof. Additionally, he has developed a pharmaceutical composition comprising at least one peptide of the invention, along with its application as a medicament.

Career Highlights

Sergio has had an impressive career working with renowned companies such as Sanofi and Société Nationale Elf Aquitaine. His work in these organizations has enabled him to push the boundaries of scientific research and innovation, particularly in developing therapeutic solutions that can improve health outcomes.

Collaborations

Throughout his career, Sergio Mallart has had the privilege of collaborating with talented professionals, including Olivier Duclos and Jean-Christophe Carry. These collaborations have fostered an environment of creativity and innovation, contributing to the advancements in his field.

Conclusion

Sergio Mallart's contributions to the field of biochemistry through his innovative patents have established him as a leading figure in the development of therapeutic peptides. His relentless pursuit of innovation and collaboration with esteemed colleagues and organizations showcases his commitment to advancing medical science. As he continues to work on groundbreaking inventions, the impact of his research promises to enhance therapeutic possibilities in the future.

This text is generated by artificial intelligence and may not be accurate.